Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
64.92
-0.54 (-0.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
45
46
Next >
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
October 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now
October 15, 2023
These companies aren't getting the respect they deserve.
Via
The Motley Fool
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
October 13, 2023
Via
Benzinga
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 12, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
October 05, 2023
Via
Benzinga
How Is The Market Feeling About Gilead Sciences?
September 21, 2023
Via
Benzinga
Gilead Sciences Unusual Options Activity
September 20, 2023
Via
Benzinga
5 Reasons Gilead Sciences is a Better Buy Than You Think
October 10, 2023
Gilead Sciences is a value and high-yielding stock on the brink of a stock rebound that could add double-digits to investors portfolios this year an next.
Via
MarketBeat
Exposures
COVID-19
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
October 10, 2023
Wall Street price targets suggest this stock can rocket more than 400% higher.
Via
The Motley Fool
Biotech Sector: On The Verge Of Triumph Or Turmoil?
October 06, 2023
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.
Via
Talk Markets
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
October 05, 2023
Low-beta stocks offer protection against market downturns and can lead to market-beating performance for investors; high yield helps
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
September 18, 2023
Via
Benzinga
Pharma Giants Combine Forces to Fight New M&A Rules
October 04, 2023
Some of pharma's biggest players — including Merck, Amgen, Abbvie, and Gilead — formed an alliance to fight looming M&A reforms.
Via
The Motley Fool
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
October 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
October 02, 2023
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.
Via
InvestorPlace
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
October 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
3 Magnificent Dividend Stocks to Buy in October
September 30, 2023
These stocks come with great dividends and more.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 29, 2023
Via
Benzinga
Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study
September 28, 2023
Gilead Sciences Inc (NASDAQ: GILD) said it has
Via
Benzinga
Exposures
COVID-19
Gilead Sciences Adapts to Economic Shifts to Support Investor Confidence
September 28, 2023
By the end of today, September 28, 2023, Gilead Sciences (NASDAQ:GILD) is set to deliver a dividend payout of $0.75 per share, equating to an annualized dividend yield of 3.96%.
Via
Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
September 27, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Gilead Sciences Inc. (NASDAQ: GILD) Making Surprising Moves in Tuesday Session
September 26, 2023
Via
Investor Brand Network
Exposures
COVID-19
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
September 21, 2023
Many stocks have nosebleed valuations. But not these.
Via
The Motley Fool
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
September 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
September 19, 2023
Good medicines aren't always good business.
Via
The Motley Fool
Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
September 18, 2023
Healthcare-sector dividend payers Pfizer, Medtronic, and Gilead all boosted shareholder payouts and trade at low multiples relative to potential price gains.
Via
MarketBeat
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
September 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
September 13, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food...
Via
FinancialNewsMedia
Exposures
Product Safety
Time For Gilead Sciences-Heavy ETFs?
September 12, 2023
Gilead Sciences has underperformed the broader market this year by a hefty margin.
Via
Talk Markets
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
September 11, 2023
Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.